Total Normal Motile Sperm Count Plays no Role in Clinical pregnancy Rate After Intrauterine Insemination

2011 ◽  
Vol 95 (4) ◽  
pp. S24 ◽  
Author(s):  
Amy Shah ◽  
Vicken Sahakian ◽  
Catherine DeUgarte
2021 ◽  
Vol 3 (1) ◽  
pp. 15-18
Author(s):  
Mehmet Sipahi ◽  
Şebnem Alanya Tosun ◽  
Sadettin Oguzhan Tutar

Objective: Determination of the clinical pregnancy rate in intrauterine insemination (IUI) cycles performed with microfluidic sperm sorting chips. Material and Methods: In Giresun University Obstetrics and Pediatrics Hospital Infertility Clinic, 133 patients who underwent IUI after ovarian stimulation with gonadotropins in unexplained infertility, mild to moderate male factor, ovulatory dysfunction, mild endometriosis were retrospectively analyzed between January 2016-January 2020. Microfluidic sperm sorting chip was used for sperm preparation. Results: The number of cycles was found to be 133. Mean female age was; 29.9±4.7 years, mean total motile sperm count was; 72.9±63.7 million, mean antral follicle count was; 18.1±10.1, the mean total gonadotropin dose used was 897.6±366 IU. Considering the causes of infertility; 54.1% unexplained, 8.3% mild male factor, 31.6% polycystic ovary syndrome (PCOS) and 6% endometriosis. The clinical pregnancy rate was found to be 19.5% (26/133). Conclusion: Microfluidic sperm sorting chips provide an increase in clinical pregnancy rates compared to conventional methods in IUI cycles and allow for a practical and rapid sperm preparation. Key Words: IUI, microfluidic sperm sorting chip, clinical pregnancy rate.


2015 ◽  
Vol 12 (1) ◽  
pp. 6-10 ◽  
Author(s):  
Tayfun Çok ◽  
Pınar Çağlar Aytaç ◽  
Erhan Şimşek ◽  
Bülent Haydardedeoğlu ◽  
Hakan Kalaycı ◽  
...  

2021 ◽  
Vol 73 (3) ◽  
pp. 198-203
Author(s):  
Padmalaya Thakur ◽  
Sujata Pradhan

Objective: To compare the efficacy of clomiphene citrate and letrozole in combination with low dose human menopausal gonadotropin for controlled ovarian stimulation in intrauterine insemination (IUI) cycles.Methods: During January-2018 to December-2019 for intending 496 IUI cycles, controlled ovarian stimulation was performed with either clomiphene or letrozole combined with human menopausal gonadotropin (hMG), in two arms:  subjects in one arm (Group A) were with clomiphene and hMG in 222 cycles; those in the second arm (Group B) were with letrozole and hMG in 274 cycles. Pregnancy rate and clinical pregnancy rate of both groups were considered as the primary outcomes.Results: Patient characteristics like female age, indications for IUI, type of IUI, endometrial thickness and total motile fraction (TMF) of spermatozoa of male partners were seen similar in both groups. The letrozole-hMG group (Group B) had significantly higher numbers of cycles with single dominant follicle (P=0.01) and human chorionic gonadotropin (hCG) was more frequently used as the ovulation trigger (P=0.03). Pregnancy rate (18.5% vs. 15.3%, P=0.35) and clinical pregnancy rate (18.5% vs. 15.3%, P=0.35) were similar in groups A and B, respectively.Conclusion: Clomiphene citrate and letrozole combined with low dose human menopausal gonadotropin were equally effective for controlled ovarian stimulation in IUI cycles.


2016 ◽  
Vol 8 (2) ◽  
pp. 140-144
Author(s):  
Azadeh Pravin Patel ◽  
Megha Snehal Patel ◽  
Sushma Rakesh Shah ◽  
Shashwat Kamal Jani

ABSTRACT Objectives To determine the predictive factors for pregnancy after stimulated intrauterine insemination (IUI). Materials and methods A retrospective analysis of 136 patients undergoing 443 stimulated IUI cycles was done in an attempt to identify significant variables predictive of treatment success. The primary outcome measures were clinical pregnancy and live birth rates. Predictive factors evaluated were female age, duration of infertility, indication for IUI, number of preovulatory follicles, and postwash total motile fraction (TMF). Results The overall clinical pregnancy rate and live birth rate were 7.2% and 5.1 per cycle respectively. The mean number of IUI cycles per patient was 3.2, the miscarriage rate was 15%, and the multiple pregnancy rate was 3.1%. Among the predictive factors evaluated, female age (age > 37 years; p = 0.039), the duration of infertility (5.36 vs 6.71 years, p = 0.032), and the TMF (between 10 and 20 million, p = 0.003) significantly influenced the clinical pregnancy rate. Conclusion The clinical management of the selected infertile couple should be performed in an expedited manner taking into consideration the age of the woman, etiology, and duration of infertility and motile fraction of sperms. How to cite this article Patel AP, Patel MS, Shah SR, Jani SK. Predictive Factors for Pregnancy after Intrauterine Insemination: A Retrospective Study of Factors Affecting Outcome. J South Asian Feder Obst Gynae 2016;8(2):140-144.


2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
D Se. Sharma

Abstract Study question Male infertility due to idiopathic oligoasthenoteratozoospermia- Does combining Letrozole as antiestrogenic with Coenzyme Q10 as antioxidant give better pregnancy rate ? Summary answer Combination of Co enzyme Q10 with Letrozole can significantly improve semen parameters and outcome of clinical pregnancy rate in idiopathic oligoasthenoteratozoospermic patients. What is known already Elevated levels of reactive oxygen species(ROS) are a major cause of idiopathic male factor infertility which results in sperm membrane lipid peroxidation, DNA damage and apoptosis leading to decrease sperm viability and motility. Antioxidant like Coenzyme Q10 have been used empiricallyin the treatment of oligoasthenozoospermia based on its ability to reverse oxidative stress and sperm dysfunction. Aromatase inhibitor like Letrozolehave been used in idiopathic male infertility by reducing estrogenic effect on spermatogenesis and reducing feedback inhibition of hypothalamopituatarygonadal axis. Thus a therapeutic strategy would need to use supplements to increase sperm energy metabilism, minimise free radical damage. Study design, size, duration Study design: prospective comperative clinical study Primary purpose: treatmenr Size: 60 infertile male attending OPD of SHRISTI HEALTHCARE diagnosed as idiopathic oligoasthenoteratozoospermia Duration: from March2018 to February 2020 Primary outcome: improvement in sperm count, motility and morphology after treatment Secondary outcome: clinical pregnancy rate and live birth rate. Participants/materials, setting, methods Exclusion criteria: Smoker, drug and alcohol abuse, medical treatment with gonadotropin and steroids, varicocele.60 patients were randomisedinto 3 groups. Gr A(N = 20) received Letrozole 2.5mg/day + Co enzyme Q10 300mg/day for 3 months, Gr B(N = 20) received Letrozole 2.5mg/day for 3 months, and Gr C(N = 20) received Coenzyme Q10 300mg/day for 3 months. History taking, general examination, semen analysis, sr.FSH,LH, Testesteron, E2 and scrotal duplex were done for all patients. Main results and the role of chance After treatment, Gr A as compared to Gr B and C showed significant imprivement in all 3 parameters of semen eg sperm count( 3.15±3.38 - 20.9±2.11, p < 0.001), sperm motility( 5.25±3.25 - 42.85±3.30, p < 0.001), sperm morphology( 2.26±7.81 - 25.89±7.05, p < 0.001). Improvement in sperm count and morphology was seen in Gr B(Letrozole gr) but not in sperm motility whereas Gr C ( Co enzyme Q10 gr)showed significant improvement in sperm motility and morphology but not in sperm count. 10 pregnancies occured during follow up period of 1 yr. Clinical pregnancy rate was 30%in Gr A(6/20), 5% in Gr B(1/20), AND 15% in Gr C( 3/20). Live birth rate was 83% in Gr A(5/6), 33.3% inGr C(1/3) whereas sponteneous abortion occured in Gr B pregnancy. Limitations, reasons for caution Limitation of my study was the small sample sizewhich could have some bias in outcome. I did not evaluate DNA fragmentation and level of ROS. Latest evidences report that evaluating ROS can be a diagnostic tool in predictingthe best responder to supplementation. Wider implications of the findings: Majority of studies had investigated the effect of antioxidant and aromatase inhibitor on semen parameter but few concluded their effect on live birth rate. Assisted reproductive techniques are expensive and not universally available, so any pharmacological agent with satisfactory effectiveness should be considered as 1st line treatment of oligoasthenoteratozoospermia. Trial registration number Not applicable


1993 ◽  
Vol 31 (1) ◽  
pp. 63-67 ◽  
Author(s):  
B. C. Su ◽  
P. J. Chan ◽  
D. R. Tredway ◽  
S. C. Pang

Sign in / Sign up

Export Citation Format

Share Document